134 related articles for article (PubMed ID: 38134746)
1. Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.
Li X; Wang C; Li S; Yin F; Luo H; Zhang Y; Luo Z; Chen Y; Wan S; Kong L; Wang X
Eur J Med Chem; 2024 Feb; 265():116054. PubMed ID: 38134746
[TBL] [Abstract][Full Text] [Related]
2. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
Wang C; Qu L; Li S; Yin F; Ji L; Peng W; Luo H; Lu D; Liu X; Chen X; Kong L; Wang X
J Med Chem; 2021 Sep; 64(17):12630-12650. PubMed ID: 34455779
[TBL] [Abstract][Full Text] [Related]
3. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA.
Wang C; Luo H; Chen X; Zhang Y; Lu D; Liu X; Yin F; Li S; Kong L; Wang X
Bioorg Chem; 2023 Oct; 139():106683. PubMed ID: 37379778
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer.
Zhang L; Zhen Y; Feng L; Li Z; Lu Y; Wang G; Ouyang L
Eur J Med Chem; 2023 Nov; 259():115648. PubMed ID: 37478560
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
7. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
9. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
12. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
[TBL] [Abstract][Full Text] [Related]
13. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
Huang Y; Dai X; Guan Z; Liu D; Ren L; Chen M; Zeng Z; Jiang J; Luo Y; He Y; Huang M; Zhao C
Int J Pharm; 2022 Jun; 622():121897. PubMed ID: 35690308
[TBL] [Abstract][Full Text] [Related]
14. Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
Wang C; Chen X; Liu X; Lu D; Li S; Qu L; Yin F; Luo H; Zhang Y; Luo Z; Cui N; Kong L; Wang X
Eur J Med Chem; 2022 Aug; 238():114462. PubMed ID: 35623249
[TBL] [Abstract][Full Text] [Related]
15. PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.
Yang AY; Choi EB; So Park M; Kim SK; Park MS; Kim MY
FEBS J; 2021 May; 288(9):2888-2910. PubMed ID: 33205541
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
17. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
Xu Y; Wu H; Huang L; Zhai B; Li X; Xu S; Wu X; Zhu Q; Xu Q
Eur J Med Chem; 2022 Jul; 237():114417. PubMed ID: 35504210
[TBL] [Abstract][Full Text] [Related]
18. A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer.
Fang W; Wang J; Ma X; Shao N; Ye K; Zhang D; Shi C; Luo L
Int J Nanomedicine; 2023; 18():6001-6019. PubMed ID: 37901361
[TBL] [Abstract][Full Text] [Related]
19. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer.
Gong R; Ma Z; He L; Jiang S; Cao D; Cheng Y
Chem Biol Interact; 2023 Sep; 382():110567. PubMed ID: 37271214
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
